中华介入放射学电子杂志
中華介入放射學電子雜誌
중화개입방사학전자잡지
2013年
1期
8-13
,共6页
方主亭%颜志平%罗剑钧%刘清欣%瞿旭东%张雯%刘凌晓%吴林霖%杨敏捷%王建华
方主亭%顏誌平%囉劍鈞%劉清訢%瞿旭東%張雯%劉凌曉%吳林霖%楊敏捷%王建華
방주정%안지평%라검균%류청흔%구욱동%장문%류릉효%오림림%양민첩%왕건화
癌,肝细胞%125 I粒子%经动脉化疗栓塞术%门静脉%癌栓
癌,肝細胞%125 I粒子%經動脈化療栓塞術%門靜脈%癌栓
암,간세포%125 I입자%경동맥화료전새술%문정맥%암전
Carcinoma,hepatocellular%Iodine-125 seed%TACE%Portal vein%Tumor thrombus
目的:研究经导管肝动脉化疗栓塞术( TACE)联合与未联合腔内125 I粒子条置入治疗原发性肝癌( HCC)伴广泛性门静脉癌栓的疗效。方法于2011年5月至2012年12月选择符合入组标准的62例HCC伴广泛性门静脉癌栓患者作为研究对象。将研究对象应用随机数字表法分为单纯行TACE组( A组,30例)和TACE联合经皮门静脉腔内置入125 I粒子条组( B组,32例)。记录两组间的不良反应事件、随访的实验室检查及腹部增强CT结果;Kaplan-Meier法计算两组间的生存时间及累计生存率,并用Log-rank检验绘制的生存率曲线。结果 A组肝内病灶客现缓解率为10.0%(CR 0例,PR 3例),B组肝内病灶客现缓解率为28.1%(CR 2例,PR 7例),两组间差异无统计学意义(χ2=3.259,P=0.071)。 B组每例患者置入(20.4±4.4)枚125 I粒子(14~32枚)。 A组无患者门静脉复通;B组门静脉通畅9例,复通率为28.1%,两组差异有统计学意义(χ2=7.734,P=0.005)。两组手术成功率为100.0%,无严重的不良反应事件发生。 A组平均生存期为(153.8±9.9) d(95%CI:134.5~173.1),中位生存期为(150.0±10.9)d(95%CI:128.6~171.4)。术后90、180、360 d生存率分别为89.7%、28.7%及0。 B组平均生存期为(221.5±19.2)d(95%CI:183.8~259.1),中位生存期为(190.0±24.7)d(95%CI:141.6~238.4)。术后90、180、360 d生存率分别为96.8%、56.0%及15.2%,两组间差异有统计学意义(χ2=10.973,P=0.001)[HR(A︰B)=2.577,95%CI:1.437~4.623,P=0.001]。 B组中门静脉通畅组(B1组)平均生存期为(306.9±45.6)d(95%CI:217.5~396.2),中位生存期为(264.0±41.7)d(95%CI:182.3~345.7)。术后90、180、360 d生存率分别为100.0%、87.5%及40.0%。门静脉闭塞组(B2组)平均生存期为(189.5±16.5)d(95%CI:157.2~221.9),中位生存期为(175.0±20.4) d(95%CI:134.9~215.1)。术后90、180、360 d生存率分别为95.5%、43.2%及6.4%。 B1组的生存时间长于B2组,两组差异有统计学意义(χ2=5.105,P=0.024)[HR(B2︰B1)=2.960,95%CI:1.100~7.969,P=0.032]。结论 TACE联合腔内125 I粒子条置入是治疗HCC伴广泛性门静脉癌栓的有效手段,能明显延长患者的生存期。
目的:研究經導管肝動脈化療栓塞術( TACE)聯閤與未聯閤腔內125 I粒子條置入治療原髮性肝癌( HCC)伴廣汎性門靜脈癌栓的療效。方法于2011年5月至2012年12月選擇符閤入組標準的62例HCC伴廣汎性門靜脈癌栓患者作為研究對象。將研究對象應用隨機數字錶法分為單純行TACE組( A組,30例)和TACE聯閤經皮門靜脈腔內置入125 I粒子條組( B組,32例)。記錄兩組間的不良反應事件、隨訪的實驗室檢查及腹部增彊CT結果;Kaplan-Meier法計算兩組間的生存時間及纍計生存率,併用Log-rank檢驗繪製的生存率麯線。結果 A組肝內病竈客現緩解率為10.0%(CR 0例,PR 3例),B組肝內病竈客現緩解率為28.1%(CR 2例,PR 7例),兩組間差異無統計學意義(χ2=3.259,P=0.071)。 B組每例患者置入(20.4±4.4)枚125 I粒子(14~32枚)。 A組無患者門靜脈複通;B組門靜脈通暢9例,複通率為28.1%,兩組差異有統計學意義(χ2=7.734,P=0.005)。兩組手術成功率為100.0%,無嚴重的不良反應事件髮生。 A組平均生存期為(153.8±9.9) d(95%CI:134.5~173.1),中位生存期為(150.0±10.9)d(95%CI:128.6~171.4)。術後90、180、360 d生存率分彆為89.7%、28.7%及0。 B組平均生存期為(221.5±19.2)d(95%CI:183.8~259.1),中位生存期為(190.0±24.7)d(95%CI:141.6~238.4)。術後90、180、360 d生存率分彆為96.8%、56.0%及15.2%,兩組間差異有統計學意義(χ2=10.973,P=0.001)[HR(A︰B)=2.577,95%CI:1.437~4.623,P=0.001]。 B組中門靜脈通暢組(B1組)平均生存期為(306.9±45.6)d(95%CI:217.5~396.2),中位生存期為(264.0±41.7)d(95%CI:182.3~345.7)。術後90、180、360 d生存率分彆為100.0%、87.5%及40.0%。門靜脈閉塞組(B2組)平均生存期為(189.5±16.5)d(95%CI:157.2~221.9),中位生存期為(175.0±20.4) d(95%CI:134.9~215.1)。術後90、180、360 d生存率分彆為95.5%、43.2%及6.4%。 B1組的生存時間長于B2組,兩組差異有統計學意義(χ2=5.105,P=0.024)[HR(B2︰B1)=2.960,95%CI:1.100~7.969,P=0.032]。結論 TACE聯閤腔內125 I粒子條置入是治療HCC伴廣汎性門靜脈癌栓的有效手段,能明顯延長患者的生存期。
목적:연구경도관간동맥화료전새술( TACE)연합여미연합강내125 I입자조치입치료원발성간암( HCC)반엄범성문정맥암전적료효。방법우2011년5월지2012년12월선택부합입조표준적62례HCC반엄범성문정맥암전환자작위연구대상。장연구대상응용수궤수자표법분위단순행TACE조( A조,30례)화TACE연합경피문정맥강내치입125 I입자조조( B조,32례)。기록량조간적불량반응사건、수방적실험실검사급복부증강CT결과;Kaplan-Meier법계산량조간적생존시간급루계생존솔,병용Log-rank검험회제적생존솔곡선。결과 A조간내병조객현완해솔위10.0%(CR 0례,PR 3례),B조간내병조객현완해솔위28.1%(CR 2례,PR 7례),량조간차이무통계학의의(χ2=3.259,P=0.071)。 B조매례환자치입(20.4±4.4)매125 I입자(14~32매)。 A조무환자문정맥복통;B조문정맥통창9례,복통솔위28.1%,량조차이유통계학의의(χ2=7.734,P=0.005)。량조수술성공솔위100.0%,무엄중적불량반응사건발생。 A조평균생존기위(153.8±9.9) d(95%CI:134.5~173.1),중위생존기위(150.0±10.9)d(95%CI:128.6~171.4)。술후90、180、360 d생존솔분별위89.7%、28.7%급0。 B조평균생존기위(221.5±19.2)d(95%CI:183.8~259.1),중위생존기위(190.0±24.7)d(95%CI:141.6~238.4)。술후90、180、360 d생존솔분별위96.8%、56.0%급15.2%,량조간차이유통계학의의(χ2=10.973,P=0.001)[HR(A︰B)=2.577,95%CI:1.437~4.623,P=0.001]。 B조중문정맥통창조(B1조)평균생존기위(306.9±45.6)d(95%CI:217.5~396.2),중위생존기위(264.0±41.7)d(95%CI:182.3~345.7)。술후90、180、360 d생존솔분별위100.0%、87.5%급40.0%。문정맥폐새조(B2조)평균생존기위(189.5±16.5)d(95%CI:157.2~221.9),중위생존기위(175.0±20.4) d(95%CI:134.9~215.1)。술후90、180、360 d생존솔분별위95.5%、43.2%급6.4%。 B1조적생존시간장우B2조,량조차이유통계학의의(χ2=5.105,P=0.024)[HR(B2︰B1)=2.960,95%CI:1.100~7.969,P=0.032]。결론 TACE연합강내125 I입자조치입시치료HCC반엄범성문정맥암전적유효수단,능명현연장환자적생존기。
Objective To compare the therapeutic effect of TACE combined with or without endovascular implantation of iodine-125 seeds strand for hepatocellular carcinoma ( HCC) with extensive portal vein tumor thrombus(PVTT)with randomized design.Methods From May-2011 to Dec 2012,62 patients of HCC with extensive PVTT who received TACE were randomized divided into group A ( conbined with , 30 cases)and group B(without,32 cases)endovascular implantation of iodine-125 seeds strand were analyzed retrospectively .TACE was performed after the iodine-125 seed strand implanted in the target segment of PVTT.Adverse events , laboratory tests and abdominal constrast CT results between two groups were compared.Kaplan-Meier method was used for analyzing for survival rate .Results The objective remission rate of lesions was 10.0%(CR in 1 and PR in 6)in group A and 28.1%(CR in 2,PR in 7)in group B(χ2 =3.259,P=0.071).The mean number of iodine-125 seed was 20.4 ±4.4(14-32) for every patient.The recanalization rate of portal vein was 28.1%in group B higher than 0 in group A(χ2 =7.734,P=0.005). Technical success rate was 100.0% for implantation of iodine-125 seeds strand in the target segment of PVTT.No serious procedure related complications occurred in two group .The mean and median survival time was(153.8 ±9.9) d(95%CI:134.5-173.1) and(150.0 ±10.9) d(95%CI:128.6-171.4) in Group A and(221.5 ±19.2)d 95%CI:183.8-259.1)and(190.0 ±24.7)d 95%CI:141.6-238.4)in Group B, respectively(χ2 =10.973,P=0.001)(HR(A︰B) =2.577,95%CI:1.437-4.623,P=0.001).The 90, 180,360 d cumulative survival rates were 89.7%,28.7%and 0 in group A and 96.8%,56.0%and 15.2%in group B,respectively.In group with recanalization of portal vein (group B1,9 cases),the mean and median survival time were(306.9 ±45.6)d(95%CI:217.5-396.2)and(264.0 ±41.7)d(95%CI:182.3-345.7), respectively and the 90,180,360 d cumulative survival rates were 100.0%,87.5%and 40.0%,respectively. While in group without recanalization of portal vein (group B2,23 cases),the mean and median survival time were(189.5 ±16.5) d (95%CI:157.2-221.9) and (175.0 ±20.4) d (95%CI:134.9-215.1), respectively and the 90,180,360 d cumulative survival rates were 95.5%,43.2%and 6.4%,respectively. There was statistically significant difference between two groups (χ2 =5.105,P=0.024)(HR(B2︰B1) =2.960,95%CI:1.100-7.969,P=0.032).Conclusion TACE combined with endovascular implantation of iodine-125 seeds strand is an effective treatment for HCC with extensive PVTT .